The forgotten tale of immunoglobulin allotypes in cancer risk and treatment [0.03%]
免疫球蛋白基因型在癌症风险和治疗中的作用被遗忘了？
Janardan P Pandey,Zihai Li
Janardan P Pandey
Monoclonal antibody (mAb) has fulfilled the promise of being the "Magic Bullet" in oncology with the clinical success of mAbs against CD20, Her-2/neu, epidermal growth factor receptor, vascular endothelial cell growth factor and others in a...
The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis [0.03%]
伊马替尼、达沙替尼和尼洛替尼治疗新诊断的慢性髓性白血病相对有效性的系统评价和网络 meta 分析
Stuart Mealing,Leticia Barcena,Neil Hawkins et al.
Stuart Mealing et al.
Objectives: Dasatinib 100 mg daily and nilotinib 600/800 mg daily have been compared to imatinib as first line treatments for CML in two recent randomised studies. However, no head to head evidence exists of the relative ...
Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma [0.03%]
针对早期B细胞受体信号传导可诱导恶性套细胞淋巴瘤发生凋亡
Mohand-Akli Boukhiar,Claudine Roger,Julie Tran et al.
Mohand-Akli Boukhiar et al.
Background: We previously showed that B-cell receptor (BCR) signaling pathways are important for in vitro survival of mantle cell lymphoma (MCL) cells. To further identify early BCR-activated signaling pathways involved i...
Clinical and laboratory characteristics of adolescents with platelet function disorders and heavy menstrual bleeding [0.03%]
青少年血小板功能障碍并重度月经过多的临床及实验室特点分析
Lawrence S Amesse,Teresa Pfaff-Amesse,William T Gunning et al.
Lawrence S Amesse et al.
Background: Platelet function disorders (PFDs) have emerged as an important etiology of heavy menstrual bleeding (HMB) in adolescents. However, neither clinical nor laboratory data have been methodically analyzed in this ...
Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors [0.03%]
人B细胞中苯扎莫司汀耐药的克服：补体依赖性细胞毒性和环氧酮不可逆蛋白酶体抑制剂的作用
Sue Ellen Verbrugge,Marjon Al,Yehuda G Assaraf et al.
Sue Ellen Verbrugge et al.
Background: In clinical and experimental settings, antibody-based anti-CD20/rituximab and small molecule proteasome inhibitor (PI) bortezomib (BTZ) treatment proved effective modalities for B cell depletion in lymphoproli...
Satoshi Ichikawa,Yasuaki Watanabe,Kei Saito et al.
Satoshi Ichikawa et al.
T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare subtype of diffuse large B-cell lymphoma, and has been reported to mainly affect lymph nodes with advanced Ann Arbor stage. We present a 69-year-old woman with a past history ...
French "real life" experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia [0.03%]
克罗法滨治疗难治或复发急性淋巴细胞白血病患儿的法国真实世界经验
Pascale Trioche,Brigitte Nelken,Gérard Michel et al.
Pascale Trioche et al.
Background: Clofarabine alone or in combination with cyclophosphamide and etoposide has shown a good efficacy and a tolerable toxicity profile in previous studies of children with relapsed or refractory leukaemia. This re...
Lily Weiß,Thomas Efferth
Lily Weiß
Polo-like kinase 1 (Plk1) is an interesting molecule both as a biomarker and as a target for highly specific cancer therapy for several reasons. Firstly, it is over-expressed in many cancers and can serve as a biomarker to monitor treatment...
Intravascular CNS lymphoma: Successful therapy using high-dose methotrexate-based polychemotherapy [0.03%]
中枢神经系统血管内淋巴瘤的治疗取得成功
Sied Kebir,Klaus Kuchelmeister,Pitt Niehusmann et al.
Sied Kebir et al.
Intravascular diffuse large B-cell lymphoma limited to the CNS (cIVL) is a very rare malignant disorder characterized by a selective accumulation of neoplastic lymphocytes (usually B cells) within the lumen of CNS blood vessels but not in t...
BIRC6 (APOLLON) is down-regulated in acute myeloid leukemia and its knockdown attenuates neutrophil differentiation [0.03%]
BIRC6(APOLLON)在急性髓系白血病中表达下降并可抑制中性粒细胞分化
Anna M Schläfli,Bruce E Torbett,Martin F Fey et al.
Anna M Schläfli et al.
Background: Inhibitors of apoptosis (IAPs) were intensively investigated in the context of cancer where they promote tumor growth and chemoresistence. Overexpression of the IAP BIRC6 is associated with unfavorable clinica...